MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-10-2023
Syneos Health Book Value 2011-2025 | SYNH
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Syneos Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.41 B | 3.24 B | 3.03 B | 2.86 B | 3.02 B | 301 M | 217 M | 392 M | 276 M | 317 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.41 B | 217 M | 1.71 B |
Quarterly Book Value Syneos Health
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.45 B | 3.5 B | - | - | 3.3 B | 3.41 B | 3.32 B | 3.24 B | 3.24 B | 3.24 B | 3.24 B | 3.24 B | 3.24 B | 3.03 B | 3.03 B | 3.03 B | 3.03 B | 2.86 B | 2.86 B | 2.86 B | 2.86 B | 3.02 B | 3.02 B | 3.02 B | 3.02 B | 301 M | 301 M | 301 M | 301 M | 217 M | 217 M | 217 M | 217 M | 392 M | 392 M | 392 M | 392 M | 276 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.5 B | 217 M | 2.11 B |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
75.7 M | $ 19.29 | -1.73 % | $ 99.4 M |  Israel |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M |  USA |
 |
Castle Biosciences
CSTL
|
456 M | $ 40.09 | -0.27 % | $ 1.11 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 21.26 | -2.34 % | $ 229 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 10.04 | -0.99 % | $ 285 M | Israel |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
BioNano Genomics
BNGO
|
35.4 M | $ 1.52 | -0.65 % | $ 1.93 M | USA |
 |
Danaher Corporation
DHR
|
77.5 B | $ 231.47 | 0.28 % | $ 169 B | USA |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | $ 101.54 | -0.05 % | $ 18.8 B | USA |
 |
DexCom
DXCM
|
2.07 B | $ 67.42 | 0.84 % | $ 26 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M |  Britain |
 |
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | USA |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 27.01 | -0.55 % | $ 817 M | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
261 M | $ 19.73 | -1.45 % | $ 1.06 B | USA |
 |
Celcuity
CELC
|
116 M | $ 102.61 | 0.25 % | $ 4.05 B | USA |
 |
Anixa Biosciences
ANIX
|
18.9 M | $ 3.42 | 3.64 % | $ 109 K | USA |
 |
Co-Diagnostics
CODX
|
86 M | $ 0.24 | -1.79 % | $ 7.04 M | USA |
 |
IQVIA Holdings
IQV
|
6.07 B | $ 226.02 | 0.39 % | $ 41 B | USA |
 |
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | Israel |
 |
Guardant Health
GH
|
-140 M | $ 102.38 | -0.12 % | $ 12.6 B | USA |
 |
NeoGenomics
NEO
|
902 M | $ 12.3 | -0.97 % | $ 1.56 B | USA |
 |
Neogen Corporation
NEOG
|
2.07 B | $ 7.14 | -0.14 % | $ 1.55 B | USA |
 |
Aspira Women's Health
AWH
|
6.73 M | - | -6.19 % | $ 10.5 M | USA |
 |
National Research Corporation
NRC
|
49 M | $ 18.81 | -1.05 % | $ 462 M | USA |
 |
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | USA |
 |
OPKO Health
OPK
|
1.37 B | $ 1.3 | -0.76 % | $ 902 M | USA |
 |
Organovo Holdings
ONVO
|
10.5 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
7.38 M | - | -16.95 % | $ 1.54 M | USA |
 |
Pacific Biosciences of California
PACB
|
701 M | $ 1.88 | 3.3 % | $ 477 M | USA |
 |
Mettler-Toledo International
MTD
|
-127 M | $ 1 417.16 | 0.18 % | $ 30.1 B |  Schweiz |
 |
Illumina
ILMN
|
6.3 B | $ 135.32 | -0.64 % | $ 21.5 B | USA |
 |
Charles River Laboratories International
CRL
|
3.51 B | $ 203.16 | 0.14 % | $ 10.4 B | USA |
 |
ENDRA Life Sciences
NDRA
|
2.56 M | $ 5.1 | - | $ 2.74 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
12 B | $ 26.98 | 0.37 % | $ 20 B |  Niderland |
 |
Personalis
PSNL
|
203 M | $ 8.41 | -0.12 % | $ 498 M | USA |
 |
PerkinElmer
PKI
|
7.67 B | - | -0.91 % | $ 14.7 B | USA |
 |
Quidel Corporation
QDEL
|
11.9 B | $ 28.91 | 1.12 % | $ 1.22 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 175.92 | 0.48 % | $ 19.5 B | USA |
|
Biodesix
BDSX
|
20.9 M | $ 6.82 | 1.04 % | $ 884 M | USA |
 |
Precipio
PRPO
|
14.4 M | $ 23.89 | 2.56 % | $ 31 M | USA |